Glycolysis Define Two Prognostic Subgroups of Lung Adenocarcinoma With Different Mutation Characteristics and Immune Infiltration Signatures

被引:4
|
作者
Huo, Chen [1 ]
Zhang, Meng-Yu [1 ]
Li, Rui [1 ]
Liu, Ting-Ting [1 ]
Li, Jian-Ping [1 ]
Qu, Yi-Qing [2 ]
机构
[1] Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Pulm & Crit Care Med,Shandong Key Lab Infect, Jinan, Peoples R China
[2] Shandong Univ, Qilu Hosp, Dept Pulm & Crit Care Med, Shandong Key Lab Infect Resp Dis, Jinan, Peoples R China
来源
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY | 2021年 / 9卷
关键词
lung adenocarcinoma; glycolysis; tumor mutational burdens; prognosis; tumor-infiltrating immune cell; INTERACTION NETWORKS; CANCER; TUMORS; INHIBITION; RESISTANCE;
D O I
10.3389/fcell.2021.645482
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Increasing studies have proved that malignant tumors are associated with energy metabolism. This study was aimed to explore biological variables that impact the prognosis of patients in the glycolysis-related subgroups of lung adenocarcinoma (LUAD). The mRNA expression profiling and mutation data in large LUAD samples were collected from the Cancer Genome Atlas (TCGA) database. Then, we identified the expression level and prognostic value of glycolysis-related genes, as well as the fractions of 22 immune cells in the tumor microenvironment. The differences between glycolysis activity, mutation, and immune infiltrates were discussed in these groups, respectively. Two hundred fifty-five glycolysis-related genes were identified from gene set enrichment analysis (GSEA), of which 43 genes had prognostic values (p < 0.05). Next, we constructed a glycolysis-related competing endogenous RNA (ceRNA) network which related to the survival of LUAD. Then, two subgroups of LUAD (clusters 1 and 2) were identified by applying unsupervised consensus clustering to 43 glycolysis-related genes. The survival analysis showed that the cluster 1 patients had a worse prognosis (p < 0.001), and upregulated differentially expressed genes (DEGs) are interestingly enriched in malignancy-related biological processes. The differences between the two subgroups are SPTA1, KEAP1, USH2A, and KRAS among top 10 mutated signatures, which may be the underlying mechanism of grouping. Combined high tumor mutational burden (TMB) with tumor subgroups preferably predicts the prognosis of LUAD patients. The CIBERSORT algorithm results revealed that low TMB samples were concerned with increased infiltration level of memory resting CD4+ T cell (p = 0.03), resting mast cells (p = 0.044), and neutrophils (p = 0.002) in cluster 1 and high TMB samples were concerned with increased infiltration level of memory B cells, plasma cells, CD4 memory-activated T cells, macrophages M1, and activated mast cells in cluster 2, while reduced infiltration of monocytes, resting dendritic cells, and resting mast cells was captured in cluster 2. In conclusion, significant different gene expression characteristics were pooled according to the two subgroups of LUAD. The combination of subgroups, TMB and tumor-infiltrating immune cell signature, might be a novel prognostic biomarker in LUAD.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] Prognostic biomarker TUBA1C is correlated to immune cell infiltration in the tumor microenvironment of lung adenocarcinoma
    Bian, Tingting
    Zheng, Miaosen
    Jiang, Daishan
    Liu, Jian
    Sun, Hui
    Li, Xiaoli
    Liu, Lei
    Zhang, Jianguo
    Liu, Yifei
    CANCER CELL INTERNATIONAL, 2021, 21 (01)
  • [42] Systematic profiling of immune signatures identifies prognostic predictors in lung adenocarcinoma
    Shuangshuang Mao
    Yuan Li
    Zhiliang Lu
    Yun Che
    Jianbing Huang
    Yuanyuan Lei
    Yalong Wang
    Xinfeng Wang
    Chengming Liu
    Sufei Zheng
    Ning Li
    Jiagen Li
    Nan Sun
    Jie He
    Cellular Oncology, 2020, 43 : 681 - 694
  • [43] Intratumor microbiome derived glycolysis-lactate signatures depicts immune heterogeneity in lung adenocarcinoma by integration of microbiomic, transcriptomic, proteomic and single-cell data
    Deng, Xiaheng
    Chen, Xiru
    Luo, Yu
    Que, Jun
    Chen, Liang
    FRONTIERS IN MICROBIOLOGY, 2023, 14
  • [44] Construction and validation of a novel immune and tumor mutation burden-based prognostic model in lung adenocarcinoma
    Zhou, Bolun
    Gao, Shugeng
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (05) : 1183 - 1197
  • [45] Comprehensive analysis of prognostic value and immune infiltration of Regulator of Chromosome Condensation 2 in lung adenocarcinoma
    Lin, Hai
    Lin, Guofu
    Lin, Lanlan
    Yang, Jiansheng
    Yang, Dongyong
    Lin, Qinhui
    Xu, Yuan
    Zeng, Yiming
    JOURNAL OF CANCER, 2024, 15 (07): : 1901 - 1915
  • [46] ADAM12 as a Clinical Prognostic Indicator Associated with Tumor Immune Infiltration in Lung Adenocarcinoma
    Pan, Junfan
    Huang, Zhidong
    Zhang, Yuan
    Xu, Yiquan
    DNA AND CELL BIOLOGY, 2022, 41 (04) : 410 - 423
  • [47] FHL1 as a novel prognostic biomarker and correlation with immune infiltration levels in lung adenocarcinoma
    Zhang, Jingtao
    Li, Haitao
    Guo, Minghao
    Zhang, Jing
    Zhang, Guangming
    Sun, Ning
    Feng, Yuyuan
    Cui, Wenqiang
    Xu, Fei
    IMMUNOTHERAPY, 2023, 15 (04) : 235 - 252
  • [48] DPYSL2 as potential diagnostic and prognostic biomarker linked to immune infiltration in lung adenocarcinoma
    Yang-Jie Wu
    Ai-Tao Nai
    Gui-Cheng He
    Fei Xiao
    Zhi-Min Li
    San-Yuan Tang
    Yan-Ping Liu
    Xiao-Hong Ai
    World Journal of Surgical Oncology, 19
  • [49] DPYSL2 as potential diagnostic and prognostic biomarker linked to immune infiltration in lung adenocarcinoma
    Wu, Yang-Jie
    Nai, Ai-Tao
    He, Gui-Cheng
    Xiao, Fei
    Li, Zhi-Min
    Tang, San-Yuan
    Liu, Yan-Ping
    Ai, Xiao-Hong
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2021, 19 (01)
  • [50] Prognostic model of lung adenocarcinoma constructed by the CENPA complex genes is closely related to immune infiltration
    Zhou, Haomiao
    Bian, Tingting
    Qian, Li
    Zhao, Cui
    Zhang, Weiju
    Zheng, Miaosen
    Zhou, Hao
    Liu, Lei
    Sun, Hui
    Li, Xiaoli
    Zhang, Jianguo
    Liu, Yifei
    PATHOLOGY RESEARCH AND PRACTICE, 2021, 228